國藥集團推動孟加拉國月產500萬劑國藥新冠疫苗分裝項目
中國國藥集團與孟加拉國新冠滅活疫苗合作,雙方簽署新冠疫苗分裝合作備忘錄。
此次國藥集團與孟加拉國Incepta公司合作,在中孟兩國政府鼎力支持下,推動月產500萬劑國藥新冠疫苗分裝項目在孟加拉國落地,助力孟加拉國戰勝新冠疫情。孟方政府和人民始終堅持選擇中國國藥集團新冠滅活疫苗,是對「中國疫苗」「中國品質」的高度認可。
國藥集團新冠滅活疫苗是第一支獲得世衛組織緊急使用認證的中國疫苗。目前,該疫苗已在9個國家註冊上市,面向全球94個國家、地區和國際組織供應,接種人羣覆蓋196個國別。60多個國家的元首和政要接種了國藥集團新冠疫苗。疫苗的安全性、有效性已得到充分驗證,對各種新冠病毒變異株具有良好的防護效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.